指南与共识乳腺病理

欧洲小叶乳腺癌联盟:浸润性小叶癌病理诊断与E-钙黏蛋白免疫组化评估整合推荐

Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.
指南 / 共识 · Mod Pathol · 2024-04-17

该推荐由欧洲小叶乳腺癌联盟制定,旨在协调浸润性小叶癌(ILC)的病理诊断。研究比较了5种常用E-钙黏蛋白抗体克隆,发现EP700Y和NCL-L-E-cad特异性降低,Clone 36与P-钙黏蛋白交叉反应;E-钙黏蛋白免疫组化提高了病理医师间诊断一致性,其染色模式与变异等位基因频率及无义介导RNA衰减可能性相关,但与CDH1突变类型或位置无关。基于此推荐了E-钙黏蛋白染色的指征、抗体选择及判读标准。

要点

  • 推荐使用E-钙黏蛋白免疫组化以提高ILC诊断的病理医师间一致性。
  • 抗体选择需注意特异性差异:EP700Y和NCL-L-E-cad特异性降低,Clone 36与P-钙黏蛋白交叉反应。
  • E-钙黏蛋白染色模式与CDH1变异等位基因频率及无义介导RNA衰减可能性相关,与突变类型或位置无关。

核心结论

  • 推荐E-钙黏蛋白免疫组化用于ILC诊断以标准化病理实践并提高诊断一致性。

研究设计与样本

  • 由欧洲小叶乳腺癌联盟制定推荐,比较5种常用E-钙黏蛋白抗体克隆(NCH-38、EP700Y、Clone 36、NCL-L-E-cad [Clone 36B5]、ECH-6)的生化特异性与免疫组化染色性能。
  • 采用条件性表达E-钙黏蛋白的小鼠细胞系进行Western blot分析。

主要发现

  • EP700Y和NCL-L-E-cad对E-钙黏蛋白特异性降低,Clone 36与P-钙黏蛋白存在交叉反应。
  • 使用免疫组化提高了病理医师对ILC、小叶原位癌和非典型小叶增生的诊断一致性。
  • E-钙黏蛋白免疫组化染色模式与变异等位基因频率和无义介导RNA衰减可能性相关,但与CDH1突变类型或位置无关。

关键数值与推荐

  • 推荐E-钙黏蛋白染色的指征、抗体选择及其判读标准以标准化ILC诊断。

临床怎么用

  • 在当前病理实践中,按推荐指征使用E-钙黏蛋白免疫组化辅助ILC诊断。
  • 选择特异性较好的E-钙黏蛋白抗体克隆,并注意EP700Y、NCL-L-E-cad及Clone 36的交叉反应问题。
  • 判读E-钙黏蛋白染色时需结合染色模式与CDH1变异等位基因频率及无义介导RNA衰减可能性的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive lobular carcinoma (ILC) is the second most frequent type of breast cancer (BC) and its peculiar morphology is mainly driven by inactivation of CDH1, the gene coding for E-cadherin cell adhesion protein. ILC-specific therapeutic and disease-monitoring approaches are gaining momentum in the clinic, increasing the importance of accurate ILC diagnosis. Several essential and desirable morphologic diagnostic criteria are currently defined by the World Health Organization, the routine use of immunohistochemistry (IHC) for E-cadherin is not recommended. Disagreement in the diagnosis of ILC has been repeatedly reported, but interpathologist agreement increases with the use of E-cadherin IHC. In this study, we aimed to harmonize the pathological diagnosis of ILC by comparing 5 commonly used E-cadherin antibody clones (NCH-38, EP700Y, Clone 36, NCL-L-E-cad [Clone 36B5], and ECH-6). We determined their biochemical specificity for the E-cadherin protein and IHC staining performance according to type and location of mutation on the CDH1 gene. Western blot analysis on mouse cell lines with conditional E-cadherin expression revealed a reduced specificity of EP700Y and NCL-L-E-cad for E-cadherin, with cross-reactivity of Clone 36 to P-cadherin. The use of IHC improved interpathologist agreement for ILC, lobular carcinoma in situ, and atypical lobular hyperplasia. The E-cadherin IHC staining pattern was associated with variant allele frequency and likelihood of nonsense-mediated RNA decay but not with the type or position of CDH1 mutations. Based on these results, we recommend the indication for E-cadherin staining, choice of antibodies, and their interpretation to standardize ILC diagnosis in current pathology practice.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. De Schepper M, Koorman T, Richard F, et al. Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium. Mod Pathol. 2024. PMID: 38641322. doi:10.1016/j.modpat.2024.100497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。